About Immunoglobulin heavy constant gamma 4
Immunoglobulin heavy constant gamma 4 (IGHG4) is a protein
from Homo sapiens identified by UniProt accession
P01861, 396 residues long.
MolForge cross-references it against 0 known binders and
150 disease associations.
Target properties
| Protein name | Immunoglobulin heavy constant gamma 4 |
| UniProt accession | P01861 |
| Gene | IGHG4 |
| Organism | Homo sapiens |
| Length | 396 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | LOW |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (150)
Diseases linked to this target (Open Targets).
- cutaneous Leishmaniasis · score 0.59
- immune deficiency, familial variable · score 0.08
- Barrett's esophagus · score 0.08
- common variable immunodeficiency · score 0.08
- combined immunodeficiency with skin granulomas · score 0.07
- hyper-IgM syndrome type 3 · score 0.07
- classic Hodgkin lymphoma · score 0.07
- Hodgkins lymphoma · score 0.07
- inborn error of immunity · score 0.07
- severe combined immunodeficiency due to CARD11 deficiency · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P01861-F1 | alphafold | PREDICTED | 86.78 | — |
Amino-acid sequence (396 residues)
ASTKGPSVFP LAPCSRSTSE STAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTKT YTCNVDHKPS NTKVDKRVES KYGPPCPSCP APEFLGGPSV FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTY RVVSVLTVLH QDWLNGKEYK CKVSNKGLPS SIEKTISKAK GQPREPQVYT LPPSQEEMTK NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPVLDS DGSFFLYSRL TVDKSRWQEG NVFSCSVMHE ALHNHYTQKS LSLSLELQLE ESCAEAQDGE LDGLWTTITI FITLFLLSVC YSATVTFFKV KWIFSSVVDL KQTIVPDYRN MIRQGA
Explore Immunoglobulin heavy constant gamma 4 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets